Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW2IF9)

Drug Name

IR502 Drug Info

Synonyms

Zorcell

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Phase 2	[1]
Psoriasis vulgaris	EA90	Phase 2	[2]
Psoriatic disorder	EA90	Phase 2	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell receptor (TCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[5]
RGI-2001	DM4AC2F	Graft-versus-host disease	4B24	Phase 2	[6]
SAR444200	DM7J5H0	Aggressive cancer	2A00-2F9Z	Phase 2	[7]
TOL-101	DM6AXV9	Multiple sclerosis	8A40	Phase 1/2	[8]
MAGE-A10 TCR	DM6H3YS	Bladder cancer	2C94	Phase 1/2	[5]
NY-ESO-TCR	DMS0L6J	Melanoma	2C30	Phase 1/2	[5]
AFP TCR	DMHBUMZ	Hepatocellular carcinoma	2C12.02	Phase 1	[5]
BPX-701	DMYERSD	Acute myeloid leukaemia	2A60	Phase 1	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008880)
4	WO patent application no. 2004,0677,06, Production of multimeric proteins.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68.
7	Clinical pipeline report, company report or official report of Sanofi
8	First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355.